Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/ISRCTN88373119
ISRCTN88373119Completed未知

Acute Myeloid Leukaemia - High Risk (AML-HR)

Medical Research Council (MRC) (UK)0 sites600 target enrollmentStarted: October 25, 2000Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
未知
Status
Completed
Sponsor
Enrollment
600
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Study Design

Study Type
Interventional

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •1. High risk acute myeloid leukaemia (AML) (de novo or secondary, except acute promyelocytic leukemia [APL])
  • •2. Suitable for intensive therapy
  • •3. Informed consent given. High risk AML is defined as:
  • •(a) Resistant disease (greater than 15% blasts in bone marrow) after one induction course
  • •(b) Refractory disease (ie not in complete remission [CR]) after two or more induction courses
  • •(c) Relapse from first CR (with more than 5% blasts in bone marrow)
  • •(d) In complete or partial remission after one induction course but with adverse cytogenic abnormalities at diagnosis

Exclusion Criteria

  • •2. Concurrent active malignancy
  • •3. Blast transformation of CML
  • •4. Relapse from second or greater CR
  • •5. Severe renal impairment (creatinine clearance less than 30 millilitres per minute)
  • •6. Pregnant, lactating or potentially fertile and not taking adequate contraceptive precautions

Investigators

Sponsor
Medical Research Council (MRC) (UK)

Similar Trials

Completed
Not Applicable
AML 12 - Acute myeloid leukaemia Adults (modified)Cancer
ISRCTN17833622Medical Research Council (MRC) (UK)
Completed
Phase 3
Adults with Acute Myeloid Leukaemia or High-Risk Myelodysplastic Syndrome (AML19)Acute myeloid leukaemia and myelodysplastic syndromeCancer
ISRCTN78449203Cardiff University (UK)1,033
Terminated
Phase 1
Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia
NCT06068868AbbVie36
Terminated
Not Applicable
CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid LeukemiaRelapsed/Refractory Acute Myeloid Leukemia(AML)
NCT03473457Zhujiang Hospital2
Active, not recruiting
Phase 1
The AML19 Trial is an intensive chemotherapy trial for patients between 16 and 60 with AML and High Risk Myelodysplastic disease (please note High Risk MDS arm is now closed).Acute myeloid leukaemiaHigh Risk Myelodysplastic SyndromeMedDRA version: 21.1Level: PTClassification code 10028533Term: Myelodysplastic syndromeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10000880Term: Acute myeloid leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2014-002195-90-DKCardiff University3,000